

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

25 Jun 2026

### The investigating of the effect of curcumin and zinc co-supplementation on glycemic measurements, lipid profiles, inflammatory and antioxidant biomarkers in pre-diabetic patients

#### Protocol summary

##### Study aim

The determining of the effect of curcumin and zinc co-supplementation on glycemic measurements, lipid profiles, inflammatory and antioxidant biomarkers in pre-diabetic patients

##### Design

a double-blind randomized controlled trial/ factorial design/ 4 parallel groups: (N=21)

##### Settings and conduct

84 patients referring to Yazd Diabetes Specialty Clinic who meet the inclusion criteria will be randomly divided into 4 groups by random sampling. General Characterization and the assessment of anthropometric, diet, Weight loss, physical activity, and biochemistry will conduct for each patient. After 3 months of supplementation, the above assessment will be re-evaluated.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Both genders age: 18-50 years, prediabetic patients, BMI=25-35 No use of blood glucose-lowering drugs, written informed consent from patients  
Exclusion criteria: Having a history of gestational diabetes,- Pregnancy or lactation in women, Use of multivitamin-mineral supplements from three months before and during the intervention, a history of weight loss surgery in the last year, weight loss plan in the last 3 months, Sensitivity to supplementation or non-compliance during the intervention, Simultaneously participate in another project, Unwillingness to continue cooperation

##### Intervention groups

pre-diabetes patients

##### Main outcome variables

insulin, fasting glucose, HbA1c, insulin resistance, insulin sensitivity, beta-cell function, serum triglyceride, serum total cholesterol, serum LDL-C, HDL-C, ALT, AST, TAC, MDA, serum zinc, IL-1B, CRP, hs-CRP,

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20190902044671N1**

Registration date: **2019-10-11, 1398/07/19**

Registration timing: **prospective**

Last update: **2020-11-13, 1399/08/23**

Update count: **1**

##### Registration date

2019-10-11, 1398/07/19

##### Registrant information

##### Name

Maryam Azhdari

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 35 3821 9196

##### Email address

azhdari\_mar@yahoo.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-11-11, 1398/08/20

##### Expected recruitment end date

2020-05-21, 1399/03/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

## Scientific title

The investigating of the effect of curcumin and zinc co-supplementation on glycemic measurements, lipid profiles, inflammatory and antioxidant biomarkers in pre-diabetic patients

## Public title

The investigating of the effect of curcumin and zinc co-supplementation on glycemic measurements, lipid profiles, inflammatory and antioxidant biomarkers in pre-diabetic patients

## Purpose

Prevention

## Inclusion/Exclusion criteria

### Inclusion criteria:

both genders age: 18-50 years (for women 18 years before menopause individuals with IFG =100-125 (mg/dL), IGT =140-199(mg/dL), or/and HbA1c=% 6.4 -5.7 , individuals with BMI=25-35 No use of blood glucose-lowering drugs such as Metformin or Glucophage individuals with written informed consent from patients

### Exclusion criteria:

## Age

From **18 years** old to **50 years** old

## Gender

Both

## Phase

3

## Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

## Sample size

Target sample size: **84**

## Randomization (investigator's opinion)

Randomized

## Randomization description

In order to prevent selection bias from occurring after randomization, the concealment allocation method will be used to assign binary codes to each individual.

## Blinding (investigator's opinion)

Double blinded

## Blinding description

Before starting the study, a person other than the researchers will code the packages including two cans according to the number of participants in the study to keep the researcher informed about the type of pills received by each group. Each individual is delivered a pack including two cans. On each can, how to use the pills will be explained. Package 1 will contain (can1: placebo for curcumin supplement (bb), and can 2: zinc supplement (AA)); package 2 will contain (can1: placebo for zinc supplement (aa), and can 2: curcumin supplement (BB)); Package 3 will contain (can 1: zinc supplementation (AA) and can 2: curcumin supplementation (BB)), package 4 will contain (can 1: placebo for curcumin supplement (aa), and can 2: placebo for zinc supplement (bb)).

## Placebo

Used

## Assignment

Factorial

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Ahvaz Jundishapur University of Medical Sciences

##### Street address

Ahvaz Jundishapur University of Medical Sciences, Golestan high way, Ahvaz, Iran

##### City

Ahvaz

##### Province

Khuzestan

##### Postal code

6135715794

#### Approval date

2019-10-05, 1398/07/13

#### Ethics committee reference number

IR.AJUMS.REC.1398.504

## Health conditions studied

### 1

#### Description of health condition studied

Pre-diabetic

#### ICD-10 code

R-73.0

#### ICD-10 code description

Abnormal glucose tolerance test

## Primary outcomes

### 1

#### Description

Fasting blood glucose

#### Timepoint

at the beginning and end of study

#### Method of measurement

serum sample

### 2

#### Description

serum insulin

#### Timepoint

at the beginning and end of study

#### Method of measurement

serum sample

### 3

**Description**

hemoglobin A1c

**Timepoint**

at the beginning and end of study

**Method of measurement**

serum sample

### 4

**Description**

serum triglyceride

**Timepoint**

at the beginning and end of study

**Method of measurement**

serum sample

### 5

**Description**

insulin resistance

**Timepoint**

at the beginning and end of study

**Method of measurement**

insulin resistance formula (HOMA-IR)

### 6

**Description**

insulin sensitivity

**Timepoint**

at the beginning and end of study

**Method of measurement**

insulin sensitivity formula

### 7

**Description**

beta-cell function

**Timepoint**

at the beginning and end of study

**Method of measurement**

formula

### 8

**Description**

total cholesterol

**Timepoint**

at the beginning and end of study

**Method of measurement**

serum sample

### 9

**Description**

serum Low Density lipoprotein -Cholesterol (LDL-C)

**Timepoint**

at the beginning and end of study

**Method of measurement**

serum sample

### 10

**Description**

serum Low Density lipoprotein -Cholesterol (HDL-C )

**Timepoint**

at the beginning and end of study

**Method of measurement**

serum sample

### 11

**Description**

Malondialdehyde (MDA)

**Timepoint**

at the beginning and end of study

**Method of measurement**

serum sample

### 12

**Description**

Total Antioxidant Capacity (TAC)

**Timepoint**

at the beginning and end of study

**Method of measurement**

serum sample

### 13

**Description**

serum zinc

**Timepoint**

at the beginning and end of study

**Method of measurement**

serum sample

### 14

**Description**

interleukin 1-B (IL-1B )

**Timepoint**

at the beginning and end of study

**Method of measurement**

serum sample

### 15

**Description**

C- Reaction Protein (CRP)

**Timepoint**

at the beginning and end of study

**Method of measurement**

serum sample

### 16

**Description**

High sensitivity C- Reaction Protein(hs-CRP)

**Timepoint**

at the beginning and end of study

**Method of measurement**

serum sample

## Secondary outcomes

### 1

**Description**

Aspartate Transaminase (AST)

**Timepoint**

at the beginning and end of study

**Method of measurement**

serum sample

### 2

**Description**

Alanine Transaminase (ALT)

**Timepoint**

at the beginning and end of study

**Method of measurement**

serum sample

### 3

**Description**

weight

**Timepoint**

at the beginning, and end of the study

**Method of measurement**

seca scales

### 4

**Description**

height

**Timepoint**

at the beginning

**Method of measurement**

stadiometer

### 5

**Description**

waist circumference

**Timepoint**

at the beginning, and end of the study

**Method of measurement**

tape

### 6

**Description**

hip circumference

**Timepoint**

at the beginning, and end of the study

**Method of measurement**

tape

### 7

**Description**

blood pressure

**Timepoint**

at the beginning, and end of the study

**Method of measurement**

Korotkoff sound technique with a calibrated mercury sphygmomanometer

### 8

**Description**

Body composition (fat mass (FM), free fat mass (FFM), muscle mass (MM))

**Timepoint**

at the beginning, and end of the study

**Method of measurement**

bioelectrical impedance analysis (BIA) method by a Body Composition Analyzer (InBody 270, Seoul, South Korea)

### 9

**Description**

Dietary intake (energy, carbohydrate, fat, protein)

**Timepoint**

at the beginning, and end of the study

**Method of measurement**

using Nutritionist IV software

### 10

**Description**

Physical activity

**Timepoint**

at the beginning, and end of the study

**Method of measurement**

Short form of the International Physical Activity Questionnaire (IPAQ-SF)

### 11

**Description**

Health-related quality of life

**Timepoint**

at the beginning, and end of the study

**Method of measurement**

SF-36 questionnaire

## Intervention groups

### 1

**Description**

Intervention group: curcumin supplement

**Category**

Treatment - Drugs

### 2

**Description**

Intervention group: zinc supplement

**Category**

Treatment - Drugs

### 3

**Description**

Intervention group: curcumin supplement+zinc supplement

**Category**

Treatment - Drugs

**4****Description**

Control group: placebo

**Category**

Placebo

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Yazd Diabetes Research Clinic

**Full name of responsible person**

Maryam Azhdari

**Street address**

Shahid bahonar Square, shihid sadoughi BLv, Yazd, Iran.

**City**

Yazd

**Province**

Yazd

**Postal code**

8916978477

**Phone**

+98 35 3728 0226

**Fax**

+98 35 3728 0216

**Email**

drc@ssu.ac.ir

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Ahvaz University of Medical Sciences

**Full name of responsible person**

Dr.Mohammad.Badavi

**Street address**

Ahvaz Jundishapur University of Medical Sciences, Golestan highway,Ahvaz, Iran,

**City**

Ahvaz

**Province**

Khouzestan

**Postal code**

6135715794

**Phone**

+98 61 3373 8383

**Fax**

+98 61 3336 1544

**Email**

azhdari\_mar@yahoo.com

**Web page address**<http://www.ajums.ac.ir>**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

No

**Title of funding source**

Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran,

**Proportion provided by this source**

60

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding***empty***Country of origin****Type of organization providing the funding**

Academic

**2****Sponsor****Name of organization / entity**

Yazd University of Medical Sciences

**Full name of responsible person**

Dr.Masood.Mirzaei

**Street address**

Shahid Sadoughi University of Medical Sciences and Health Services, Shahid bahonar Square, shihid sadoughi BLv, Yazd, Iran.

**City**

Yazd

**Province**

Yazd

**Postal code**

8915173160

**Phone**

+98 35 3724 0173

**Email**

azhdari\_mar@yahoo.com

**Web page address**<http://www.ssu.ac.ir>**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Yazd University of Medical Sciences

**Proportion provided by this source**

40

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding***empty***Country of origin****Type of organization providing the funding**

Academic

## Person responsible for general inquiries

### Contact

**Name of organization / entity**

Ahvaz University of Medical Sciences

**Full name of responsible person**

Maryam Azhdari

**Position**

Ph.D Student

**Latest degree**

Master

**Other areas of specialty/work**

Nutrition

**Street address**

Department of clinical biochemistry, Faculty (school) of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Saffaeieh, Alem Square, Shohadaye Gomnan BLv, Yazd, Iran.( Postal Code: 8916178477)

**City**

Yazd

**Province**

Yazd

**Postal code**

8916116364

**Phone**

+98 35 3821 9196

**Fax****Email**

azhdari\_mar@yahoo.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Ahvaz University of Medical Sciences

**Full name of responsible person**

Maryam Azhdari

**Position**

Ph.D Student

**Latest degree**

Master

**Other areas of specialty/work**

Nutrition

**Street address**

Department of clinical biochemistry, Faculty (school) of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Saffaeieh, Alem Square, Shohadaye Gomnan BLv, Yazd, Iran.( Postal Code: 8916178477)

**City**

Yazd

**Province**

Yazd

**Postal code**

8916116364

**Phone**

+98 35 3821 9196

**Fax****Email**

azhdari\_mar@yahoo.com

## Person responsible for updating data

### Contact

**Name of organization / entity**

Ahvaz University of Medical Sciences

**Full name of responsible person**

Maryam Azhdari

**Position**

Ph.D Student

**Latest degree**

Master

**Other areas of specialty/work**

Nutrition

**Street address**

Department of clinical biochemistry, Faculty (school) of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Saffaeieh, Alem Square, Shohadaye Gomnan BLv, Yazd, Iran.( Postal Code: 8916178477)

**City**

Yazd

**Province**

Yazd

**Postal code**

8916116364

**Phone**

+98 35 3821 9196

**Fax****Email**

azhdari\_mar@yahoo.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available

**Title and more details about the data/document**

all data is related to primary and secondary outcome, will be reported.

**When the data will become available and for how long**

After the manuscript publication.

**To whom data/document is available**

After publication, it will be possible for everyone.

**Under which criteria data/document could be used**

Using the documentation with citation 1- To conduct

similar and extensive research 2- To use the method of a project 3. To write systematic Review and meta-analysis articles

**From where data/document is obtainable**

1- Refer to the Library of Ahvaz Jundishapur University of Medical Sciences 1-Refer to the Library of Yazd University of Medical Sciences 3- Email to Maryam Azdari: azhdari\_mar@yahoo.com)

**What processes are involved for a request to access data/document**

Everyone can use the data Referring to the library of the above-mentioned universities or by the emailing, for received data by email, it will be necessary to explain the reason for the using the data completely and clearly. He/she will be received within a maximum of one week.

**Comments**